Agile Therapeutics was Downgraded to a Hold Rating at William Blair

By Ryan Adsit

Agile Therapeutics (NASDAQ: AGRX) received a Hold rating from William Blair analyst Tim Lugo today. The company’s shares opened today at $2.57, close to its 52-week low of $1.82.

According to, Lugo is a 4-star analyst with an average return of 16.0% and a 40.0% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Aclaris Therapeutics Inc, and CoLucid Pharmaceuticals.

Currently, the analyst consensus on Agile Therapeutics is Moderate Buy and the average price target is $6.50, representing a 152.9% upside.

In a report issued on December 22, Janney Montgomery also downgraded the stock to Hold.

Based on Agile Therapeutics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $0 and GAAP net loss of $7.1 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $7.8 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. engages in the development and commercialization of new prescription contraceptive products. Its product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company was founded on December 22, 1997 and is headquartered in Princeton, NJ.